| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 75, 669-670, Copyright © 1992 by Endocrine Society
ARTICLES |
ST Wilson, DE Blask and AM Lemus-Wilson
Mary Imogene Bassett Hospital, Research Institute, Cooperstown, New York 13326-1394.
Cultured MCF-7 human breast cancer cells were pre-exposed to either melatonin (232 ng/mL) or vehicle for 24 hrs prior to being washed and then re-exposed to either ethanol-vehicle or varying concentrations of tamoxifen (37.1 ng/mL, 3.71 micrograms/mL, 371 micrograms/mL) or melatonin (2.32 pg/mL, 232 ng/mL, 23.2 ng/mL) for 5 additional days. Only 371 ng/mL tamoxifen caused a 38% growth inhibition of cells pre- exposed to vehicle whereas all concentrations of tamoxifen inhibited the growth of melatonin pre-exposed cells by 28% to 61% in a dose- dependent manner. Melatonin pre-exposure, potentiated the inhibitory effect of only 232 ng/mL melatonin. Comparison of IC50 values indicate that tamoxifen is approximately a 100 times more potent inhibitor of breast cancer cell growth following the pretreatment of cells with a physiological concentration of melatonin. These results indicate that melatonin has the capability to augment the inhibitory actions of tamoxifen, and to a lesser extent itself, on human breast cancer cell growth.
This article has been cited by other articles:
 |
|
 |
|
  F. Mahmoud, N. Sarhill, and M. A. Mazurczak The therapeutic application of melatonin in supportive care and palliative medicine American Journal of Hospice and Palliative Medicine, July 1, 2005; 22(4): 295 - 309. [Abstract] [PDF]
|
|
|
|
 |
|
 B. del Rio, J. M. G. Pedrero, C. Martinez-Campa, P. Zuazua, P. S. Lazo, and S. Ramos Melatonin, an Endogenous-specific Inhibitor of Estrogen Receptor {alpha} via Calmodulin J. Biol. Chem., September 10, 2004; 279(37): 38294 - 38302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Izzo, M. d'Istria, I. Serino, and S. Minucci Inhibition of the increased 17{beta}-estradiol-induced mast cell number by melatonin in the testis of the frog Rana esculenta, in vivo and in vitro J. Exp. Biol., February 1, 2004; 207(3): 437 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Vijayalaxmi, C. R. Thomas Jr, R. J. Reiter, and T. S. Herman Melatonin: From Basic Research to Cancer Treatment Clinics J. Clin. Oncol., May 15, 2002; 20(10): 2575 - 2601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Jacobson, S. B. Workman, and F. Kronenberg Research on Complementary/Alternative Medicine for Patients With Breast Cancer: A Review of the Biomedical Literature J. Clin. Oncol., February 1, 2000; 18(3): 668 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. GARCÍA RATO, J. GARCÍA PEDRERO, M. A. MARTÍNEZ, B. DEL RIO, P. S. LAZO, and S. RAMOS Melatonin blocks the activation of estrogen receptor for DNA binding FASEB J, May 1, 1999; 13(8): 857 - 868. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
